Physician profile
Yin Tun
NPI 1679927875
$4,348.21
in general payments reported to CMS, 2019-2025
31 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $306 · 2024: $1,738 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,275 · Education: $73.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.78 |
| Education | $73.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $529.75 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $431.73 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $353.66 | 2023-2025 | |
| Amgen INC. | $347.18 | 2023-2025 | Evenity, Tepezza, Prolia |
| Astrazeneca Pharmaceuticals LP | $282.57 | 2024-2025 | Lokelma, Farxiga |
| Xeris Pharmaceuticals, INC. | $210.29 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Ascendis Pharma Endocrinology INC | $209.00 | 2025 | Yorvipath |
| Novo Nordisk INC | $207.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $189.01 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Recordati_rare_diseases_inc. | $157.95 | 2025 | Isturisa, Enjaymo |
| Sanofi-Aventis U.S. LLC | $137.28 | 2023-2025 | |
| Cequr Corporation | $136.65 | 2024-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $126.62 | 2024-2025 | |
| Insulet Corporation | $112.21 | 2024-2025 | Omnipod |
| Amphastar Pharmaceuticals, INC. | $108.81 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $96.48 | 2024-2025 | |
| Intra-Sana Laboratories | $88.93 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Dexcom, INC. | $81.00 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $78.55 | 2024-2025 | Nexletol |
| Pfizer INC. | $67.13 | 2024-2025 | |
| Madrigal Pharmaceuticals | $64.74 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $49.71 | 2024-2025 | Licart, Tirosint, Flector |
| Alexion Pharmaceuticals, INC. | $47.74 | 2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.15 | 2023-2024 | Cycloset |
| Averitas Pharma INC. | $43.18 | 2024-2025 | Qutenza |
| Beta Bionics, INC. | $28.92 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Currax Pharmaceuticals LLC | $28.45 | 2025 | Contrave |
| Ionis Pharmaceuticals, INC. | $24.70 | 2025 | Tryngolza |
| Tolmar, INC. | $23.65 | 2024 | |
| Almatica Pharma LLC | $20.16 | 2025 | Teriparatide |
| Horizon Therapeutics Plc | $19.59 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yin Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.